CN-121987627-A - Application of compound JQB-22 or pharmaceutically acceptable salt thereof in preparation of antitubercular drugs

Abstract

The invention discloses an application of a compound JQB-22 or pharmaceutically acceptable salt thereof in preparing an antituberculosis drug, and relates to the technical field of biological medicines. The invention discovers that the compound JQB-22 has the effect of inhibiting the intracellular survival of the tubercle bacillus at the level of macrophages, can obviously enhance the anti-tuberculosis effect by regulating and controlling the host immunity, and shows better control of the tubercle bacillus capacity in lung tissues compared with the traditional first-line anti-tuberculosis drug ethambutol. The compound JQB-22 provided by the invention has the potential of being developed as an antitubercular drug. The invention provides innovative research direction and preclinical candidate medicine for solving the dilemma of drug-resistant tuberculosis treatment.

Inventors

• CHENG YONGXIAN
• CHEN XINCHUN
• HUANG DANLING
• ZHANG KEHONG
• JIANG QINBIN
• CAI NINGJIAN
• CHEN GUANGHUAN

Assignees

• 深圳大学

Dates

Publication Date

20260508

Application Date

20260325

Claims (8)

1. 1. Use of a compound JQB-22 or a pharmaceutically acceptable salt thereof as sole active ingredient in the manufacture of an antitubercular drug, said compound JQB-22 having the structural formula: 。
2. 2. The use according to claim 1, wherein the antitubercular medicament is for the prevention or treatment of infection by mycobacterium tuberculosis.
3. 3. The use according to claim 1, wherein the antitubercular drug inhibits mycobacterium tuberculosis proliferation by enhancing macrophage bactericidal function.
4. 4. The use of claim 1, wherein the antitubercular drug inhibits the intracellular survival of tubercle bacillus by targeting the host to modulate the host immune response.
5. 5. Use of compound JQB-22 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for preventing or treating a disease caused by mycobacterium tuberculosis infection.
6. 6. The use according to claim 5, wherein the disease comprises tuberculosis.
7. 7. A pharmaceutical composition for preventing or treating a disease caused by a mycobacterium tuberculosis infection, comprising compound JQB-22 or a pharmaceutically acceptable salt thereof.
8. 8. The pharmaceutical composition of claim 7, further comprising a pharmaceutically acceptable excipient, carrier, and/or diluent.

Description

Application of compound JQB-22 or pharmaceutically acceptable salt thereof in preparation of antitubercular drugs Technical Field The invention relates to the technical field of biological medicines, in particular to application of a compound JQB-22 or pharmaceutically acceptable salt thereof in preparation of antitubercular medicines. Background Tuberculosis is a chronic infectious disease caused by infection with mycobacterium tuberculosis (tuberculosis). Due to the lack of effective vaccines, current tuberculosis control strategies are mainly early discovery and early treatment. The drug treatment is not only the key for reducing the death rate of tuberculosis, but also the key for reducing the spread of tuberculosis, so that the drug treatment is the most effective means in the current tuberculosis prevention and treatment practice. Short-range chemotherapy regimens recommended by the world health organization are currently used in our country, and include treatment with various combinations of first-line antitubercular drugs Isoniazid (INH), rifampicin (RFP), pyrazinamide (PZA), streptomycin (SM), ethambutol (EMB), etc. In recent years, quinolones have been increasingly used in the treatment of tuberculosis patients. Although the use of these drugs saves the lives of more than 2 tens of millions of tuberculosis patients, the current tuberculosis treatment drugs obviously cannot meet the requirements of patients and tuberculosis prevention and treatment. Because of the occurrence of tubercle bacillus drug resistance, especially the occurrence of multi-drug resistance and wide drug resistance, the prevention and the treatment of tuberculosis face serious challenges. Therefore, there is a need for the development of novel (highly effective and low-toxic) antitubercular drugs that are highly effective in controlling tuberculosis. Disclosure of Invention The invention aims to solve the technical problem of providing an application of a compound in preparing a medicine for preventing or treating tuberculosis. In order to solve the problems, the invention provides the following technical scheme: The invention provides an application of a compound JQB-22 or pharmaceutically acceptable salt thereof as a unique active ingredient in preparing an antitubercular drug, wherein the compound JQB-22 has the following structural formula: 。 Further, the antitubercular drug is used for preventing or treating infection of mycobacterium tuberculosis. Further, the antitubercular drug inhibits proliferation of mycobacterium tuberculosis by enhancing macrophage bactericidal function. Further, the antitubercular drug is used for inhibiting the intracellular survival of tubercle bacillus by targeting a host to regulate the host immune response. The invention also provides application of the compound JQB-22 or pharmaceutically acceptable salt thereof in preparing a medicament for preventing or treating diseases caused by mycobacterium tuberculosis infection. Further, the disease includes tuberculosis. The invention provides a pharmaceutical composition for preventing or treating diseases caused by mycobacterium tuberculosis infection, which comprises a compound JQB-22 or pharmaceutically acceptable salts thereof. Further, the pharmaceutical composition further comprises pharmaceutically acceptable excipients, carriers and/or diluents. Further, the dosage forms of the pharmaceutical composition comprise sugar-coated tablets, film-coated tablets, enteric-coated tablets, capsules, hard capsules, soft capsules, oral liquid, buccal agents, granules, medicinal granules, pills, pellets, suspension, powder, wine, preparation, drops, injection, powder injection, cream, sustained release agents, targeting agents and the like. Further, the pharmaceutical composition can be applied to prevention or treatment of tuberculosis caused by mycobacterium tuberculosis infection. The tuberculosis includes, but is not limited to, drug-resistant tuberculosis, non-drug-resistant tuberculosis, primary tuberculosis, secondary tuberculosis, blood group disseminated tuberculosis, tracheobronchial tuberculosis, tuberculous pleurisy, mycoyin tuberculosis, etc. Compared with the prior art, the invention has the following technical effects: The theoretical source of Host-directed therapy (Host-DIRECTED THERAPY, HDT) can be traced back to the deep resolution of pathogen interaction mechanisms at the end of the 20 th to the beginning of the 21 st century. The core idea is to indirectly inhibit the survival of pathogens by regulating and controlling the immune response or metabolic process of a host, and not directly kill bacteria, so that the problem of drug resistance of the traditional antibiotics is solved. The invention discovers that the compound JQB-22 has the effect of inhibiting the intracellular survival of the tubercle bacillus at the level of macrophages, can obviously enhance the anti-tuberculosis effect by regulating and controlling the host immunity